{"url_path":"/sec/maze/10-q/2026/item-2","section_key":"item-2","section_title":"Item 2 Unregistered Sales of Equity Securities, Use of Proceeds, and Issuer Purchases of Equity Securities","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-12","source_url":"https://www.sec.gov/Archives/edgar/data/1842295/0001193125-26-219430-index.html","accession_number":"0001193125-26-219430","cik":"0001842295","ticker":"MAZE","issuer_name":"Maze Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1842295/0001193125-26-219430-index.html","primary_entity_key":"0001842295","primary_entity_name":"Maze Therapeutics, Inc."},"word_count":369,"has_tables":true,"body_markdown":"Item 2. Unregistered Sales of Equity Securities, Use of Proceeds, and Issuer Purchases of Equity Securities\n\nUnregistered Sale of Securities.\n\nOn September 10, 2025, we entered into a securities purchase agreement with certain selling stockholders, pursuant to which we issued and sold an aggregate of (i) 4,000,002 shares of common stock at a purchase price of $16.25 per share and (ii) in lieu of shares of common stock for certain selling stockholders, warrants to purchase up to an aggregate of 5,231,090 shares of common stock at a purchase price of $16.249 per warrant, resulting in gross proceeds to us of $150.0 million. For the year ended December 31, 2025, warrants to purchase 900,000 shares of our common stock were exercised. No warrants were exercised for the three months ended March 31, 2026 and as of March 31, 2026, warrants to purchase 4,331,090 shares of our common stock remained outstanding.\n\nThis transaction was exempt from registration requirements of the Securities Act in reliance upon Section 4(a)(2) of the Securities Act or Regulation D promulgated under the Securities Act.\n\nUse of Initial Public Offering Proceeds.\n\nOn January 30, 2025, our registration statement on Form S-1 (File No 333-284164) relating to our initial public offering of common stock was declared effective by the U.S. Securities and Exchange Commission, or the SEC. Upon the closing of the initial public offering on February 3, 2025, we issued 8,750,000 shares of common stock at a public offering price of $16.00 per share, resulting in net proceeds of approximately $127.8 million, after deducting underwriting discounts, commissions and other payable offering expenses of approximately $12.2 million. J.P. Morgan Securities LLC, TD Securities (USA) LLC, Leerink Partners LLC and Guggenheim Securities, LLC acted as joint book-running managers for the offering. None of the expenses associated with our initial public offering were paid, directly or indirectly, to any of our directors or officers, any persons owning 10% or more of any class of equity securities, or to any of our affiliates.\n\nThere has been no material change in the planned use of proceeds from the initial public offering as described in the prospectus filed with the SEC pursuant to Rule 424(b)(4) under the Securities Act on January 31, 2025."}